Carl E. Berg is Co-Founder, Chairman of the Board and Principal Investor of BERG. Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million sq. feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc. From 1997 until its sale in 2012. Mission West Properties was a public real estate investment trust with Microsoft & Apple as major tenants.
Mitch Gray is a Co-Founder a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation management and operations functions to startup companies with a current focus on the biopharma industry. Mr. Gray oversaw operational expansion of the Berg sites in Boston and Nashville and directed key finance and legal functions across all business units. He has international B2B experience within the Asian and Sub-Saharan African markets and has also overseen operations in real estate and timberland holdings in California.
Niven R. Narain is Co-Founder, President, & CEO of BERG. His foremost passion is to improve healthcare systems and patient care through the fusion of AI and patient biology to develop the next generation of therapeutics. As CEO, Niven drives the vision of the translational engine from discovery to clinical development and ensures that BERG is collaborating with like-minded institutions to advance product development. He discovered Interrogative Biology®, BERG’s flagship platform that has created a robust pipeline of products in cancer, diabetes, and CNS diseases. BPM 31510 is BERG’s lead asset in solid tumors which is currently in Phase II trials. He is inventor on over 600 issued and pending patents over a diverse range of assets in drugs and diagnostics.